

A Comparative Study of Group Behavioral Activation and Cognitive Therapy in Reducing Subsyndromal Anxiety and Depressive Symptoms

Mehdi Soleimani, PhD¹
 Parvaneh Mohammadkhani, PhD²
 Behroz Dolatshahi, PhD²
 Hamid Alizadeh, PhD³
 Karenleigh A. Overmann, MA⁴
 Frederick L. Coolidge, PhD⁴

¹ Department of Psychiatry,
 Tehran University of Medical
 Sciences, Tehran, Iran

² University of Social Welfare and
 Rehabilitation Sciences, Tehran,
 Iran

³ Allameh Tabataba'i University,
 Tehran, Iran

⁴ Department of Psychology,
 University of Colorado, Colorado
 Springs, USA

Corresponding author:

Mehdi Soleimani, PhD
 Department of Psychiatry,
 Roozbeh Psychiatric hospital,
 Tehran University of Medical
 Sciences, Tehran, Iran,
 Tel: +98-2155419151.
 E-mail: soleimaniphd@yahoo.com

Objective: This study compared the effectiveness of two group treatments, behavioral activation (BA) and cognitive therapy (CT), in reducing subsyndromal anxiety and depressive symptoms in a sample of Iranian university students.

Method: Twenty-seven Iranian university students who scored 18 or higher on the depression subscale and 16 or higher on the anxiety subscale of the Depression, Anxiety, and Stress Scale (DASS-42) were randomly assigned into treatment groups. One group received 8 sessions of BA (n = 14), and the other received 8 sessions of group CT (n = 13).

Result: Analysis of covariance revealed that the BA group had a significantly greater reduction in depressive symptoms than the CT group. However, there were no significant differences between the two groups in the levels of anxiety, stress symptoms or functional impairment after treatment.

Conclusion: This study found evidence for the effectiveness of BA in reducing anxiety, depressive and stress symptoms and functional impairment compared to CT. BA was more effective than CT in improving depressive symptoms and was as effective as CT in decreasing anxiety, stress and functional impairment. BA is also a cost-effective intervention, particularly in group formats.

Keywords: Behavioral Activation Therapy, Cognitive Therapy, Subsyndromal Anxiety and Depressive Symptoms, Functional Impairment

Iran J Psychiatry 2015; 10:2: 71-78

According to the World Health Organization (WHO), anxiety and depressive disorders are the most common and prevalent mental disorders, with anxiety disorders as the most prevalent mental disorder (1, 2). The rate of comorbidity between anxiety and depressive disorders is also significant (3, 4). For example, the average rate of comorbidity between major depressive disorder and anxiety disorders exceeds 50% (5).

Subsyndromal anxiety and depression, though clinically failing to meet formal diagnostic criteria, has a significant potential to impair day-to-day functioning (6). Despite the fact that subsyndromal anxiety and depressive symptoms have a tendency to become chronic, they often receive little clinical attention, prompting the need to develop effective treatment strategies (7–9). Moreover, patients with subsyndromal anxiety and depressive symptoms are at greater risk than the general population for developing clinical anxiety and depressive disorders when faced with psycho-social stressors (10).

Epidemiological studies have found an elevated rate of anxiety and depressive symptoms in university students in Iran (11–13), with symptomatic severity interfering with students' ability to function in the educational setting (14).

Cognitive therapy (CT) and behavior therapy have demonstrated effectiveness in treating anxiety and depressive disorders (15–17). There is evidence suggesting that current psychotherapy models can reduce subsyndromal symptoms (18). Moreover, a new trend in the psychotherapy research, the transdiagnostic (unified) approach (19, 20), emphasizes the common etiology among emotional disorders, providing support for taking a dimensional (rather than categorical) approach to comorbid mental disorders (21). The transdiagnostic approach has several important features: It is easy to train clinicians to administer the interventions, it has the capacity to be implemented in a group setting, it can be applied to comorbid anxiety and depression, and it has demonstrated effectiveness in preventing relapse in recovery from emotional disorders (22, 23). Furthermore, the transdiagnostic approach does not

require formal clinical diagnosis of a psychiatric disorder (22).

Outcome studies have indicated the efficacy of CT for a variety of mental disorders, including major depressive disorder, generalized anxiety disorder, panic disorder and social anxiety disorder (16, 24). CT is also effective in the treatment of mixed anxiety–depressive disorders (25) and in heterogeneous anxiety disorders in group format (26). Furthermore, preventive studies with at-risk populations indicate the potential effectiveness of CT-based programs (27, 28). Alternatively, medication (Fluvoxamine and Sertraline) has also demonstrated efficacy for treating mixed anxiety-depressive disorder in short-term periods (8 weeks) of treatment (29, 30).

Behavioral activation (BA) is a behaviorally-oriented psychotherapy that helps clients identify and modify inactivity and avoidance patterns (31). It was originally developed to treat depression (32) and has shown efficacy for treating this disorder (16, 33). BA has also been used to treat other disorders that are considered as emotion dysregulation, including anxiety disorders (34).

Avoidant behavior plays a key role in fostering and maintaining anxiety disorders and depression. For example, depressed patients are frequently involved in avoidant behaviors like complaining, which means they often lose any chance of gaining positive reinforcement (35). These insights into the connection between avoidant behavior and anxiety and depressive disorders inform both behavior therapy (which helps patients regulate their emotions by changing their behavior (36)) and exposure and response prevention (ERP, an empirically validated psychotherapy for anxiety disorders (16, 37)).

Because BA targets avoidant behaviors, the treatment is appropriate for managing comorbid anxiety and depression (34, 38). There is some early evidence showing that BA can decrease symptoms of posttraumatic stress disorder and comorbid major depressive disorder (39, 40). Pilot studies have shown that BA has positive effects in decreasing anxiety symptoms in chronic anxiety and coexistent depressive and anxiety symptoms (41, 42). Chu and colleagues (43) also found that group BA therapy had clinical benefits for anxious and depressed young adolescents.

Group and short-term modalities yield several benefits, including cost-effectiveness and an ability to cover more patients than is possible with individual therapies or long-term treatments (44). Group and individual therapies have demonstrated similar effectiveness in treatment outcomes (45), and the reduced complexity of BA makes it consistent with the transdiagnostic approach (33, 46).

It is important to note that there have been a number of recent empirical studies that support the use of BA and CT in a variety of settings and populations (e.g., see 47–56). Thus, the purpose of this study was to

compare the effectiveness of group BA treatment and group CT to reduce subsyndromal anxiety and depressive symptoms, stress symptoms and functional impairment in Iranian university students.

Material and Methods

Participants

Participants were Iranian university students ($n = 32$) recruited through advertisements in several universities in Tehran. This sample size was determined on the basis of Cohen's table (57) for a power of .08, alpha of .05, and an effect size of .80. The sample size exceeded the recommendation of Butler and colleagues (24), who suggest that a small number of participants ($n = 9$) is acceptable in studies of cognitive therapies for depression and anxiety. There were a total of 20 female participants, with 11 being assigned to the BA condition; of the seven male participants, three were assigned to the BA condition. The average age of the participants was 22 years for the BA condition and 23 years for the CT condition. Of the 14 participants assigned to the BA condition, only one was married, while in the 13 participants in the CT condition, two were married. These demographics are presented in Table 1.

Criteria for participant inclusion in the study were the existence of subsyndromal anxiety and depressive symptoms as measured by a score of 18 or higher on the depression subscale and 16 or higher on the anxiety subscale of the Depression, Anxiety and Stress Scale (DASS-42). This cutoff was selected to reflect the criteria used by Sahebi and colleagues (58) in their study on validating DASS-21 findings in a sample of an Iranian population, in which a score of 9 on the depression subscale and a score of 8 on the anxiety subscale of the DASS-21 indicated inclusion in the 75th percentile and a mild level of symptom severity. The items of the DASS-21 were selected to reflect all of the subscales, and the DASS-21 subscale scores were multiplied by 2 to create the DASS-42 scales. Exclusion criteria were the existence of current Axis I disorders, including anxiety, depression, psychotic, somatoform or substance abuse, assessed by diagnostic interviews based on the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) (59) and simultaneously being on prescribed medication or in psychotherapy. All participants agreed to participate in the study and provided written informed consent.

The dropout criterion was three absences in eight sessions, consistent with the recommendation of Gollan and colleagues (60). Two participants dropped out of the BA condition, and three dropped out of the CT condition, reducing the total number of participants to 27. One participant left after two CT sessions due to dissatisfaction with the intervention relative to perceived needs. Another participant in the CT condition was unable to continue with the intervention following the death of a family member. Three other participants dropped out due to schedule conflicts.

Materials and Procedure

A Comparative Study of Group Behavioral

This study compared two groups of BA as the experimental condition and CT as the comparison condition. Participants were randomly assigned into one of the groups. CT was considered the comparison condition because of its demonstrated efficacy in treating depressive and anxiety disorders (15, 17) and its widespread use as a psychotherapeutic treatment (62). CT is also the most well-known and widely used psychotherapy in Iran, and its individual and group formats have been subjected to numerous investigations in treating Iranian patients (63–66). Thus, the CT condition was considered to be the standard of comparison for the treatments in this study. CT presented the additional benefits of enabling control of non-specific therapeutic factors (e.g., contacting the therapist and attending treatment sessions) and provided an ethical treatment alternative for the comparison group.

Recruitment advertisements were placed at several Iranian universities. Volunteers were individually evaluated onsite to confirm their eligibility for the study and obtain informed consent. For determining eligibility, a clinical interview using ADIS-IV and DASS-42 was conducted for each participant. To measure functional impairment, the participants were asked to complete the Work and Social Adjustment Scale (WSAS) (67). Participants were then randomly assigned into either the BA or the CT treatment groups. Each treatment group consisted of 16 participants who received eight sessions of group intervention led by a trained therapist. To meet the recommended participant-to-therapist ratio (68), each group was further divided into two 8-member groups. One therapist conducted both BA subgroups, while the CT sessions had separate therapists for each subgroup. To ensure therapist compliance with the CT manual, peer supervision was used. Each CT therapist attended three sessions (sessions 1, 4, and 6) conducted by the other therapist as a co-therapist to monitor adherence to the manual. After each session, the two therapists discussed the session's process and content and provided recommendations to improve compliance with the manual. Finally, all participants completed the DASS-42 and the WSAS at the post-treatment assessment.

Treatment and Therapists

BA treatment followed the guidelines of Gollan and Martell and colleagues (31, 60, 61) and consisted of eight group sessions. Each session had an agenda for the therapist to follow (outlined in Table 2) and lasted for 90 minutes. The primary goal of BA is to teach the participants to identify the patterns of behavior (especially avoidance behaviors) associated with anxiety and depressive symptoms, and to change the behaviors in ways that improve emotional regulation. Participants were encouraged to stop avoiding situations that led to feelings of anxiety and depression in favor of making changes that could positively alter emotional states. Participants were also encouraged to

increase their level of life activity to increase their possibilities of feeling enjoyment and accomplishment. CT followed the published guidelines (68). As in the BA condition, CT consisted of eight group sessions, each of which was implemented by a therapist according to a pre-established agenda (Table 2) and lasted for 90 minutes.

Participants in the CT condition were asked to identify relations between their thoughts and emotions, automatic thoughts and cognitive distortions. They were then encouraged to challenge them with cognitive techniques.

The two CT therapists were both PhD students in a clinical psychology program with at least 2 years of experience in the psychotherapy of anxiety and depressive disorders obtained in university counseling centers. They were also trained in cognitive behavioral therapy for the treatment of anxiety and depressive disorders. Prior to the study, they reviewed treatment manuals, and during the study, they received copies of session agendas.

Measures

Anxiety, Depressive and Stress Symptoms: The Depression, Anxiety and Stress Scale (DASS) (69) was used to assess anxiety, depressive and stress symptoms. The DASS is a 42-item self-report questionnaire developed to measure three relevant emotions (depression, anxiety and stress). This questionnaire has a 21-item form. The measure is a valid and reliable instrument for the Iranian population, as assessed by Sahebi and colleagues (58) for the DASS-21 and by Bakhshipour and Dejkam (70) for the DASS-42. Sahebi and colleagues also established the construct validity of the DASS-21 in Iranian samples through factor analysis, and they found the internal reliability (Cronbach's α) of the DASS-21 in an adult Iranian sample of $\alpha = .77$ for the depression subscale, $\alpha = .79$ for anxiety subscale and $\alpha = .78$ for stress subscale. Moreover, Bakhshipour and Dejkam reported α coefficients for the DASS-42 subscales, depression, anxiety and stress, respectively, of $\alpha = .97$, $\alpha = .92$, and $\alpha = .94$. The construct validity of the DASS-42 was also established through factor analysis (70).

Diagnostic Interview: The Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) (59) was used to determine the diagnostic status of the participants. The ADIS-IV is a reliable structured interview designed to assess current anxiety disorders based on DSM-IV criteria. The ADIS-IV provides the possibility to assess current mood, somatoform and substance use disorders. The interview also screens for conversion and psychotic symptoms. Brown, Di Nardo, Lehman and Campbell (71) reported good reliability for the lifetime version of the ADIS-IV (ADIS-IV-L) based on kappa coefficients ranging from .58 to .81.

Functional Impairment: In order to assess functional impairment, the five-item Work and Social Adjustment Scale (WSAS) was used, which has been shown to be a valid and reliable tool to assess anxiety and depressive disorders (67). We evaluated psychometric

characteristics of the WSAS in a pilot study with a sample of Iranian university students ($N = 67$, age mean = 22.8 years, standard deviation of age = 2.3 years). According to this evaluation, there was a positive and significant Pearson correlation between the WSAS and the depression subscale of the DASS-21 and the Anxiety subscale of the DASS-21, respectively, $r = .66$, $p < .001$ and $r = .66$, $p < .001$. Test-retest reliability in a one week period for the WSAS was $r = .69$, $p < .001$ ($n = 32$).

Results

Participants who were assigned into the two conditions did not differ in their gender, age or marital status (Table 1).

Analysis of Variance (ANOVA) was used to determine

the equivalence of the treatment conditions on outcome measures at the pretest point.

The results did not indicate a significant difference between BA and CT conditions on outcome measures at the pretest point for depressive symptoms, $F(1, 25) = 1.13$, $p > .05$; for anxiety symptoms, $F(1, 25) = 0.02$, $p > .05$; for stress symptoms, $F(1, 25) = 1.44$, $p > .05$; for functional impairment, $F(1, 25) = 0.18$, $p > .05$. These results demonstrated the success of random assignment in producing equivalent groups on these variables at the pretest point.

To analyze the effect of each treatment condition on outcome measures, the paired t test was used. Results are presented in Table 3. All paired t tests were significant at $p < .01$. These results indicated a significant difference between the pretest and posttest scores of each outcome measure in the BA and CT

Table 1: Participant Characteristics by Treatment Condition

Variable	Behavioral Activation (n = 14)		Cognitive Therapy (n = 13)		F(1, 25)	$\chi^2(N = 1, 27)$
	M (SD)	n %	M (SD)	n %		
Gender		11 78.6		9 69.2		.31
Female		3 21.4		4 30.8		
Male						
Age	22.28 (3.07)		23.46 (3.41)		.89	
Marriage		13 92.0		11 84.6		.46
Single		1 7.1		2 15.4		
Married						

Table 2: Session Agenda by Treatment Condition

Session	Condition	
	Behavioral Activation ^a	Cognitive Therapy ^b
1	Negative emotions: Anxiety and depressive symptoms	The three systems model of human emotion and ABC model
2	BA model of anxiety and depression (the role of negative life events, avoidance from situations and others, and rumination in maintaining negative emotions)	Cognitive theory of anxiety and depression (core beliefs, automatic thoughts, negative cognitive triad, and logical errors)
3	Pleasure-accomplishment rating and developing a pleasure activity chart	Thought injection and vertical arrow procedure
4	ACTION skill	Advanced vertical arrow and categorizing beliefs
5	TRAP and TRAC skill	Changeability of beliefs, objective analysis, and utility analysis
6	Stress, depression and anxiety	Logical analysis
7	Assertiveness	countering
8	Review of program and maintenance plan	Review of program and maintenance plan

Note: ABC = activating event, belief and emotional consequences; ACTION = assess, choose, try, integrate, observe result and never give up; TRAP = trigger, response and avoidance pattern; TRAC = trigger, response and alternative coping.

^a Adapted from (60).

^b Adapted from (68).

Table 3: Means, Standard Deviations and ANCOVA Results for the Outcome Measures

Variable	Behavioral Activation (n = 14)			Cognitive Therapy (n = 13)			F(1,24)
	Pretest M (SD)	Posttest M (SD)	Paired t(13) ^a	Pretest M (SD)	Posttest M (SD)	Paired t(12) ^a	
DASS-D	23.71(3.83)	12.36(5.98)	8.19	22.15(3.78)	16.46(4.52)	4.81	7.80 ^b
DASS-A	20.93(4.03)	12.57(5.12)	6.97	20.69(3.68)	11.46(4.05)	5.99	.35
DASS-S	20.50(4.52)	13.21(3.26)	6.80	18.54(3.93)	11.77(2.98)	5.94	.48
WSAS	19.93(6.13)	13.14(6.69)	3.48	18.85(7.02)	12.54(5.78)	4.74	.00

Note: DASS-D = depression subscale of the DASS; DASS-A = anxiety subscale of the DASS; DASS-S = stress subscale of the DASS; WSAS = functional impairment.

^a All paired t values were significant at $p < .01$.

^b $p < .05$.

A Comparative Study of Group Behavioral

conditions, meaning that both treatments reduced the severity of depressive, anxiety and stress symptoms, as well as functional impairment.

To compare the BA and CT conditions on the outcome measures, Analysis of Covariance (ANCOVA) was used with pretest scores as the covariate. The ANCOVA results and the means and standard deviations of the outcome measures at the pretest and posttest points are presented in Table 3.

The BA condition showed a significantly higher effectiveness relative to the CT condition in treating depressive symptoms, $F(1, 24) = 7.80$, $p < .05$, partial $\eta^2 = .24$ (a large effect), but there was no difference between the two treatment conditions in improving anxiety and stress symptoms or functional impairment ($p > .05$) for anxiety symptoms, partial $\eta^2 = .01$; for stress symptoms, partial $\eta^2 = .02$; for functional impairment, partial $\eta^2 = .00$. The effect size (Cohen's d) for BA relative to CT was also calculated from the ANCOVA F value (72): For depressive symptoms, $d = -0.86$; for anxiety symptoms, $d = 0.21$; for stress symptoms, $d = 0.24$; for functional impairment, $d = 0.01$. A negative d score was interpreted as indicating the greater effectiveness of BA relative to CT, and a positive d score as indicating the greater effectiveness of CT relative to BA.

According to the definition of a clinically significant change (73), two treatment conditions were compared to determine whether either one moved participants from the range considered dysfunctional to the range assessed as functional. Based on the normative data on the Iranian population for the DASS provided by Sahebi and colleagues (58), cutoff points between the normal level and the level of mild symptom severity were selected for the three subscales. Where Sahebi and colleagues reported different cutoff points for men and women, the present study established different cutoff points to assess the percentage of participants in each condition indicating a clinically significant change in symptom severity.

For depressive symptoms, 71% of the participants of BA condition ($n = 10$) were assessed to be in the functional range, compared with 31% of CT participants ($n = 4$). For anxiety symptoms, 50% of BA participants ($n = 7$) showed a clinically significant improvement in symptoms, compared to 61% of the CT participants ($n = 8$). Finally, all participants in both conditions reached the functional range in stress symptoms.

Discussion

This study compared the effectiveness of BA and CT administered in group settings in university students with subsyndromal anxiety and depressive symptoms. The results revealed that both treatments could decrease the severity of symptoms and functional impairments in participants. However, BA was more effective than CT in reducing depressive symptoms as assessed through both statistical and clinical

significance. This finding was consistent with a previous, large sample investigation (33) that found BA was more effective than CT in treating severely depressed patients. The effect size reported by Dimidjian and colleagues (33) for the Beck Depression Inventory (BDI) was 0.87 (a large effect), which was comparable to the effect size found by the present study ($d = 0.86$). In addition to demonstrating greater effectiveness in managing depressive symptoms relative to CT, BA has several advantages. Jacobson and colleagues (46) demonstrated that the BA component of the full CT protocol can be as effective as the full CT protocol, making it easier and less costly to implement. Furthermore, BA is more easily applied to patients and trained in therapists than CT (31, 33). BA and CT were similarly effective in reducing anxiety, stress symptoms and functional impairment. The finding of this study revealed that BA effectively reduced anxiety symptoms, which is consistent with previous studies (41–43), and it is noteworthy because currently there is only one technique in the BA manual that directly addresses anxiety issues and prescribes exposure treatment. Although there were no in vivo exposure exercises in BA sessions, therapists encouraged participants to expose and stop avoiding. Of course, the characteristics of the present sample might limit the generalization of these findings.

Limitations and Future Directions

This was a pilot study; and as a result, there were several limitations. First, the sample size was not large, possibly limiting the generalizability of the results. Therefore, future studies should consider increasing the sample size to improve generalizability. Second, the CT condition in the present study was a subset rather than the full protocol, and this may limit its effectiveness, which can be increased when implemented with other techniques in the complete CT protocol. Finally, the sample was taken from a specific, highly educated population, and the findings might be limited to this population. Future studies should compare the BA and CT interventions on other populations, including clinical samples. Furthermore, it may be useful to investigate the preventive effect of BA and explore the mechanisms of change in the intervention.

Conclusions

Participants in the present study had subsyndromal symptoms of anxiety and depression. As noted previously, these symptoms can lead to the significant functional impairments (6, 14). As found by this study, BA is an effective treatment for these symptoms and may be preferable to CT in terms of cost and ease of implementation. On the other hand, medications are often prescribed for these symptoms (29, 30), with CT being the most commonly prescribed form of psychotherapy (62), so patients suffering from these symptoms are likely to receive CT treatment interventions in clinical settings. Thus, this study offers BA as an effective alternative to CT in clinical settings.

The effects of both treatments on anxiety and depressive symptoms indirectly support the notion that a common etiology underlies depressive and anxiety disorders, and it is consistent with the transdiagnostic approach (19, 20) to go beyond the current diagnostic categories and develop simpler intervention.

In summary, this study found positive evidence for the effectiveness of BA in reducing anxiety, depressive and stress symptoms and functional impairment relative to CT. BA was more effective than CT in improving depressive symptoms and was as effective as CT in decreasing anxiety, stress and functional impairment. BA is also a cost-effective intervention, particularly in group formats for clients and managed care.

Acknowledgement

This investigation was conducted as Mehdi Soleimani's PhD dissertation at the University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Conflict of interest

There were no conflicts of interest.

References

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiat* 2005; 62: 617–627.
2. Lambert KG. Rising rates of depression in today's society: consideration of roles of effort-based rewards and enhanced resilience in day-to-day functioning. *Neurosci Biobehav R* 2006; 30: 497–510.
3. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. *J Abnorm Psychol* 2001; 110: 585–599.
4. Cox BJ, Clara IP, Enns MW. Posttraumatic stress disorder and the structure of common mental disorders. *Depress Anxiety* 2002; 15: 168–171.
5. Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorders. *Annu Rev Psychol* 1998; 49: 377–412.
6. Dozois DJA, Westra HA. The nature of anxiety and depression: implications for prevention. In: Dozois DJA, Dobson KS, eds. *The prevention of anxiety and depression: the theory, research, and practice*. Washington, DC: American Psychological Association; 2004.
7. Goldney RD, Fisher LJ, Dal Grande E, Taylor AW. Subsyndromal depression: prevalence, use of health services and quality of life in an Australian population. *Soc Psych Psych Epid* 2004; 39: 293–298.
8. Lavretsky H, Kumar A. Clinically significant non-major depression: old concepts, new insights. *Am J Geriat Psychiat* 2002; 10: 239–255.
9. Rivas-Vazquez RA, Saffa-Biller D, Ruiz I, Blais MA, Rivas-Vazquez A. Current issues in anxiety and depression: comorbid, mixed, and subthreshold disorders. *Professional Psychology: Research and Practice* 2004; 35: 74–83.
10. Katon W, Roy-Byrne P. Mixed anxiety and depression. *J Abnorm Psychol* 1991; 100: 337–345.
11. Amini F, Farhadi A. The prevalence of anxiety and depression, and their effects on educational performance among university students of Lorestan medical university. *Abstract Collection of First Seminar on Mental Health of University Students*. Tehran: University of Tehran; 2001.
12. Mosayebi A, Verhram F, Behbahani AA, Shamloo F, Javadi M. The study of personality type, depression and anxiety rate with self-report questionnaires in medical, dental, & nursing students. *Thesis for medical degree*. Ghazvin: Ghazvin Medical University; 1995.
13. Narimani M. The prevalence and causes of anxiety in Mohaghegh Ardabili's university students. *Abstract Collection of First Seminar on Mental Health of University Students*. Tehran: University of Tehran; 2001.
14. Sohrabi F, Nobakht M. The relationship between mental health and educational achievement in Tehran university students. *Abstract Collection of First Seminar on Mental Health of University Student*. Tehran: University of Tehran; 2001.
15. Chambless DL, Baker MJ, Baucom DH, Beutler LE, Calhoun KS, Crits-Christoph P, et al. Update on empirically validated therapies, II. *The Clinical Psychologist* 1998; 51: 3–16.
16. Chambless DL, Ollendick TH. Empirically supported psychological interventions: controversies and evidence. *Annu Rev Psychol* 2001; 52: 685–716.
17. Task Force on Promotion and Dissemination of Psychological Procedures. Training in and dissemination of empirically-validated psychological treatments. *The Clinical Psychologist* 1995; 48: 3–23.
18. Barkham M, Shapiro DA, Hardly GE, Rees A. Psychotherapy in two-plus-one sessions: outcomes of a randomized controlled trial of cognitive-behavioral and psychodynamic-interpersonal therapy for subsyndromal depression. *J Consult Clin Psych* 1999; 67: 201–211.
19. Norton PJ. An open trial of transdiagnostic cognitive-behavioral group therapy for anxiety disorders. *Behav Ther* 2008; 39: 242–250.
20. Norton PJ, Hayes SA, Hope DA. Effects of a transdiagnostic group treatment for anxiety on secondary depressive disorders. *Depress Anxiety* 2004; 20: 198–202.
21. Allen BA, McHugh RK, Barlow DH. Emotional disorders: a unified approach. In: Barlow DH, ed. *Clinical handbook of psychological disorders: a step-by-step treatment manual*. 4th ed. New York: Guilford; 2007.
22. Clark DA, Taylor S. The transdiagnostic perspective on cognitive-behavioral therapy for anxiety and depression: new wine for old wineskins? *Journal of Cognitive Psychotherapy* 2009; 23: 60–66.
23. Dozois DA, Seeds PM, Collins KA. Transdiagnostic approaches to the prevention of depression and

A Comparative Study of Group Behavioral

- anxiety. *Journal of Cognitive Psychotherapy* 2009; 23: 44–59.
24. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. *Clin Psychol Rev* 2006; 26: 17–31.
 25. Echeburua E, Salaberria K, Corral P, Cenea R, Berasategui T. Treatment of mixed anxiety–depression disorder: long-term outcome. *Behav Cogn Psychoth* 2006; 34: 95–101.
 26. Erickson DH. Group cognitive behavioural therapy for heterogeneous anxiety disorders. *Cognitive Behaviour Therapy* 2003; 32: 179–186.
 27. Konnert C, Dobson K, Stelmach L. The prevention of depression in nursing home residents: a randomized clinical trial of cognitive-behavioral therapy. *Aging Ment Health* 2009; 13: 288–299.
 28. Stice E, Burton E, Bearman SK, Rohde P. Randomized trial of a brief depression prevention program: an elusive search for a psychosocial placebo control condition. *Behav Res Ther* 2007; 45: 863–876.
 29. Carrasco JL, Díaz-Marsá M, Sáiz-Ruiz J. Sertraline in the treatment of mixed anxiety and depression disorder. *J Affect Disorders* 2000; 59: 67–69.
 30. Rousch JL, MacHobby H, Shendarkar N, Johnson ME, Li J. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. *Journal of Clinical Psychopharmacology* 2001; 21: 139–142.
 31. Martell CR, Addis ME, Jacobson NS. Depression in context: strategies for guided action. New York: Norton; 2001.
 32. Jacobson NS, Martell CR, Dimidjian S. Behavioral activation treatment for depression: returning to contextual roots. *Clin Psychol—Sci Pr* 2001; 8: 255–270.
 33. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psych* 2006; 74: 658–670.
 34. Syzdek MR, Addis ME, Martell CR. Working with emotion and emotion regulation in behavioral activation treatment for depressed mood. In: Kring AM, Sloan DM, eds. *Emotion regulation and psychopathology: a transdiagnostic approach to etiology and treatment*. New York: Guilford; 2010.
 35. Ferster CB. A functional analysis of depression. *Am Psychol* 1973; 28: 857–870.
 36. Mowrer OH. Two-factor learning theory: versions one and two. In: Mowrer OH, ed. *Learning theory and behavior*. Hoboken: Wiley; 1960.
 37. Foa E, Franklin M. Obsessive–compulsive disorder. In: Barlow DH, ed. *Clinical handbook of psychological disorders: a step-by-step treatment manual*. 3rd ed. New York: Guilford Press; 2001.
 38. Hopko DR, Robertson SMC, Lejuez CW. Behavioral activation for anxiety disorders. *The Behavior Analyst Today* 2006; 7: 212–224.
 39. Jakupack M, Roberts LJ, Yoshimoto D, Mulick PS, Martell C, Balsam KF, et al. Behavioral activation for the treatment of PTSD. *J Trauma Stress* 2006; 19: 387–391.
 40. Turner AP, Jakupcak M. Behavioral activation for treatment of PTSD and depression in an Iraq combat veteran with multiple physical injuries. *Behav Cogn Psychoth* 2010; 38: 355–361.
 41. Hopko DR, Lejuez CW, Hopko SD. Behavioral activation as an intervention for coexistent depressive and anxiety symptoms. *Clinical Case Studies* 2004; 3: 37–48.
 42. Turner JS, Leach JD. Brief behavioral activation treatment of chronic anxiety in an older adult. *Behav Change* 2009; 26: 214–222.
 43. Chu BC, Colognori D, Weissman AS, Bannon K. An initial description and pilot of group behavioral activation therapy for anxious and depressed youth. *Cogn Behav Pract* 2009; 16: 408–419.
 44. Kazdin AE. *Research design in clinical psychology*. 2nd ed. Boston: Allyn & Bacon; 1992.
 45. McRoberts C, Burlingame GM, Hoag MJ. Comparative efficacy of individual and group psychotherapy: a meta-analytic perspective. *Group Dyn—Theory Res* 1998; 2: 101–117.
 46. Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, et al. A component analysis of cognitive-behavioral treatment for depression. *J Consult Clin Psych* 1996; 64: 295–304.
 47. Masterson C, Ekers D, Gilbody S, Richards D, Toner-Clewes B, McMillan D. Sudden gains in behavioural activation for depression. *Behav Res Ther* 2014; 60: 34–38.
 48. Kanter JW, Santiago-Rivera AL, Santos MM, Nagy G, López M, Hurtado GB, et al. A randomized hybrid efficacy and effectiveness trial of behavioral activation for Latinos with depression. *Behav Ther* (in press); Available online 28 September 2014.
 49. Folke F, Hursti T, Tungström S, Söderberg P, Ekselius L, Kanter JW. Behavioral activation between acute inpatient and outpatient psychiatry: description of a protocol and a pilot feasibility study. *Cogn Behav Pract* (in press); Available online 2 May 2014.
 50. Chartier IS, Provencher MD. Behavioural activation for depression: efficacy, effectiveness and dissemination. *J Affect Disorders* 2013; 145: 292–299.
 51. Chen J, Liu X, Rapee RM, Pillay P. Behavioural activation: a pilot trial of transdiagnostic treatment for excessive worry. *Behav Res Ther* 2013; 51: 533–539.
 52. Mewton L, Andrews G. Cognitive behaviour therapy via the internet for depression: a useful strategy to reduce suicidal ideation. *J Affect Disorders* 2015; 170: 78–84.
 53. Newby JM, Williams AD, Andrews G. Reductions in negative repetitive thinking and metacognitive beliefs during transdiagnostic Internet cognitive behavioural therapy (iCBT) for mixed anxiety and depression. *Behav Res Ther* 2014; 59: 52–60.
 54. Vaziri S, Jamshidifar Z, Darbani SA. The effectiveness of cognitive group therapy decreasing the symptoms of depression. *Procedia—Social and Behavioral Sciences* 2011; 30: 2173–2179.
 55. Macrodimitris S, Wershler J, Hatfield M, Hamilton K, Backs-Dermott B, Mothersill K, et al. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety. *Epilepsy Behav* 2011; 20: 83–88.
 56. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus AH. A randomized controlled trial of cognitive behavioral therapy for anxiety and

- depression in COPD. *Resp Med* 2010; 104: 986–994.
57. Christensen LB. *Experimental methodology*. 8th ed. Boston: Allyn and Bacon; 2001.
 58. Sahebi A, Asghari MJ, Salari RS. Validation of depression anxiety and stress scale (DASS-21) for an Iranian population. *Journal of Iranian Psychologists* 2005; 1: 299–312.
 59. Brown TA, Di Nardo PA, Barlow DH. *Anxiety disorders interview schedule*. 4th ed. Boulder: Graywind; 1994.
 60. Gollan J, Atlis M, Marlow-O'Connor M. *Behavioral activation: Group treatment for depression (pilot version)*. Unpublished manual. Chicago: University of Chicago; 2003.
 61. Martell CR, Dimidjian S, Herman-Dunn R. *Behavioral activation for depression: a clinician's guide*. New York: Guilford; 2010.
 62. Rachman S. Psychological treatment of anxiety: the evolution of behavioral therapy and cognitive behavioral therapy. *Annu Rev Clin Psychol* 2009; 5: 97–119.
 63. Akhond-Makkeie Z, Sanaiezaker B. The effect of group cognitive therapy based on Beck's procedure to treat depressed 15–17 year-old teen girls at ShahinShahr in Isfahan city Unpublished master's thesis. Tehran: University of Tarbiat Moallem; 1997.
 64. Izadi M, Sanaie B, Kianmanesh A. The effect of developmental-cognitive therapy on trait and state anxiety in two groups of 19–29 year-old boys and girls at Ahvaz city. Unpublished master's thesis. Tehran: University of Tarbiat Moallem 2002.
 65. Joharifard R. The effect of group cognitive-behavioral therapy in patients with generalized anxiety disorder. Unpublished master's thesis. Shiraz: Shiraz University; 2005.
 66. Komeili-Sani H, Dejkam M. Effect of cognitive therapy in depression rate of nursing students at Abadan nursing and obstetrics faculty at academic year 1995–96. Unpublished master's thesis. Tehran: University of Tarbiat Modarres; 1996.
 67. Mundt JC, Marks IM, Shear MK, Greist JH. The work and social adjustment scale: a simple measure of impairment in functioning. *Brit J Psychiat* 2002; 180: 461–464.
 68. Free ML. *Cognitive therapy in groups: guidelines and resources for practice*. Chichester: Wiley; 1999.
 69. Lovibond SM, Lovibond PFM. *Manual for the Depression Anxiety Stress Scales*. 2nd ed. Sydney: Psychology Foundation; 1995.
 70. Bakhshipour A, Dejkam M. Confirmatory factor analysis of the Positive and Negative Affect Scale. *J Psychol* 2006; 9: 351–365.
 71. Brown TA, Di Nardo, PA, Lehman CL, Campbell LA. Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders. *J Abnorm Psychol* 2001; 110: 49–58.
 72. Borenstein M. Effect sizes for continuous data. In: Cooper H, Hedages LV, Valentine JC, eds. *The handbook of research synthesis and meta-analysis*. New York: Russell Sage Foundation; 2009.
 73. Jacobson NS, Truax PA. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. *J Consult Clin Psych* 1991; 59: 12–19.